DDInter204 DDInter1676
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
Bicalutamide {u} (Compound) binds {v} (Gene) AR
Bicalutamide {u} (Compound) upregulates {v} (Gene) USP6NL
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Bicalutamide {u} (Compound) downregulates {v} (Gene) TUBB6
Bicalutamide {u} (Compound) causes {v} (Side Effect) Melaena
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Bicalutamide (Compound) resembles Enzalutamide (Compound)
Bicalutamide (Compound) treats prostate cancer (Disease)
Bicalutamide (Compound) binds AR (Gene)
Bicalutamide (Compound) upregulates USP6NL (Gene)
Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Bicalutamide (Compound) downregulates TUBB6 (Gene)
Bicalutamide (Compound) causes Melaena (Side Effect)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine